12/3
07:02 pm
bntc
Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC) [Yahoo! Finance]
Medium
Report
Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC) [Yahoo! Finance]
11/24
08:05 am
bntc
Benitec Biopharma (NASDAQ:BNTC) was given a new $32.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.
Medium
Report
Benitec Biopharma (NASDAQ:BNTC) was given a new $32.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.
11/18
07:20 am
bntc
Benitec Biopharma (NASDAQ:BNTC) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Low
Report
Benitec Biopharma (NASDAQ:BNTC) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
11/18
06:32 am
bntc
Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment [Yahoo! Finance]
Neutral
Report
Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment [Yahoo! Finance]
11/18
05:40 am
bntc
Hedge funds investors have a lot riding on Benitec Biopharma Inc. (NASDAQ:BNTC) with 37% ownership [Yahoo! Finance]
Neutral
Report
Hedge funds investors have a lot riding on Benitec Biopharma Inc. (NASDAQ:BNTC) with 37% ownership [Yahoo! Finance]
11/14
05:11 pm
bntc
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update [Yahoo! Finance]
Low
Report
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update [Yahoo! Finance]
11/14
05:00 pm
bntc
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
Medium
Report
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
11/6
12:19 am
bntc
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
High
Report
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
11/5
04:43 pm
bntc
Benitec Biopharma Inc. Announces Proposed Public Offering
High
Report
Benitec Biopharma Inc. Announces Proposed Public Offering
11/4
12:38 pm
bntc
Benitec Biopharma (NASDAQ:BNTC) had its price target raised by analysts at HC Wainwright from $28.00 to $35.00. They now have a "buy" rating on the stock.
Low
Report
Benitec Biopharma (NASDAQ:BNTC) had its price target raised by analysts at HC Wainwright from $28.00 to $35.00. They now have a "buy" rating on the stock.
11/4
08:43 am
bntc
Benitec Biopharma (NASDAQ:BNTC) was given a new $22.00 price target on by analysts at JMP Securities.
Low
Report
Benitec Biopharma (NASDAQ:BNTC) was given a new $22.00 price target on by analysts at JMP Securities.
11/4
08:09 am
bntc
Benitec Biopharma (NASDAQ:BNTC) had its price target raised by analysts at Citizens Jmp from $20.00 to $22.00. They now have a "market outperform" rating on the stock.
Low
Report
Benitec Biopharma (NASDAQ:BNTC) had its price target raised by analysts at Citizens Jmp from $20.00 to $22.00. They now have a "market outperform" rating on the stock.
11/4
07:21 am
bntc
Benitec Biopharma (NASDAQ:BNTC) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Benitec Biopharma (NASDAQ:BNTC) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
11/3
07:10 am
bntc
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
Medium
Report
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
11/3
07:00 am
bntc
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
Medium
Report
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
11/2
07:00 pm
bntc
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
Medium
Report
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
10/8
12:15 pm
bntc
Benitec Biopharma (NASDAQ:BNTC) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Benitec Biopharma (NASDAQ:BNTC) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/24
09:06 am
bntc
Benitec Biopharma (NASDAQ:BNTC) had its "market outperform" rating reaffirmed by analysts at JMP Securities. They now have a $20.00 price target on the stock.
Medium
Report
Benitec Biopharma (NASDAQ:BNTC) had its "market outperform" rating reaffirmed by analysts at JMP Securities. They now have a $20.00 price target on the stock.
9/22
04:29 pm
bntc
Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update [Yahoo! Finance]
Low
Report
Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update [Yahoo! Finance]
9/22
04:05 pm
bntc
Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update
Low
Report
Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update
9/16
10:06 am
bntc
Benitec Biopharma (NASDAQ:BNTC) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
Benitec Biopharma (NASDAQ:BNTC) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..